Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2025
vol. 29
 
Share:
Send email
Share:
Original paper

Immunometabolic landscape of glioblastoma – a comparative analysis of circulating cytokines and biochemical markers

Mamatova Irodakhon Yusupovna
1
,
Ulugbekova Gulruh Juraevna
2
,
Mamajonov Zafar Abdujalilovich
2
,
Askarov Ibragim Rakhmonovich
3

  1. Biochemistry Department, Andijan State Medical Institute, Andijan, Uzbekistan
  2. Department of Anatomy and Clinical Anatomy, Andijan State Medical Institute, Andijan, Uzbekistan
  3. Department of Chemistry, Andijan State University, Andijan, Uzbekistan
Contemp Oncol (Pozn) 2025; 29 (4): 377–383
DOI: https://doi.org/10.5114/wo.2025.156117
Online publish date: 2025/11/11
Article file
- Immunometabolic.pdf  [0.10 MB]
Get citation
 
PlumX metrics:
 
1. Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 2022; 24: v1-v95.
2. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S (ed.). Glioblastoma [Internet]. Brisbane (AU): Codon Publications 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470003/.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taph- oorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Bran- ger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Acta Neuropathol 2021; 142: 153-171.
5. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 2020; 70: 299-312.
6. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31: 326-341.
7. Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. J Neurochem 2022; 162: 205-217.
8. Garzon-Muvdi T, Yin W, Lim M. Role of inflammation and cytokines in glioma initiation and progression. Neuroimmunol Neuroinflammation 2022; 9: 38-48.
9. Kim S, Kim KH, Jung HW, Jeong EO, Lee HJ, Kwon J, et al. Elevated serum IL-6 as a negative prognostic biomarker in glioblastoma: integrating bioinformatics and clinical validation. J Cancer 2025; 16: 802-811.
10. De Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone CN. The role of IL-10 in the tumor microenvironment. Int J Mol Sci 2022; 23: 3112.
11. Kfoury N, Qi Z, Prager BC, Wilkinson MN, Broestl L, Berrett KC, et al. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma. Cancer Cell 2021; 39: 1081-1100.e8.
12. Jarmuzek P, Kozlowska K, Defort P, Kot M, Zembron-Lacny A. Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis. Cancers (Basel) 2023; 15: 3339.
13. Rocha Pinheiro SL, Lemos FFB, Marques HS, Silva Luz M, de Oliveira Silva LG, Faria Souza Mendes Dos Santos C, et al. Immunotherapy in glioblastoma treatment: current state and future prospects. World J Clin Oncol 2023; 14: 138-159.
14. Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med 2015; 3: 121.
15. Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero Cazares H. Sex-specific differences in glioblastoma. Cells 2021; 10: 1783.
16. Johnson KJ, Schwartzbaum J, Kruchko C, Scheurer ME, Lau CC, Woehrer A, et al. Brain tumor epidemiology in the era of precision medicine: The 2017 Brain Tumor Epidemiology Consortium meeting report. Clin Neuropathol 2017; 36: 255-263.
17. Zhao W, Zhang Z, Xie M, Ding F, Zheng X, Sun S, et al. Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy. NPJ Precis Oncol 2025; 9: 126.
18. Musca B, Russo MG, Tushe A, Magri S, Battaggia G, Pinton L, et al. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors. Front Immunol 2023; 14: 1236824.
19. Chen DS, Mellman I. Oncology meets immunology: the cancer- immunity cycle. Immunity 2017; 39: 1-10.
20. Wang J, He Y, Hu F, Hu C, Sun Y, Yang K, et al. Metabolic reprogramming of immune cells in the tumor microenvironment. Int J Mol Sci 2024; 25: 12223.
21. Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol 2018; 14: 482-495.
22. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017; 168: 613-628.
23. Yang W, Warrington NM, Taylor SJ, Carrasco E, Singleton KW, Wu N, et al. Sex differences in GBM: molecular, clinical and therapeutic implications. Front Oncol 2021; 11: 617851.
24. Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst 2019; 111: 772-781.
25. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23: 1231-1251.
26. Kruk PA, Dekker MCJ, Haaxma CA, Sillevis Smitt P, van den Bent MJ, Taphoorn MJB. Sex disparities in glioma incidence and survival: hormonal influences and genetic factors. J Neuro Oncol 2015; 123: 397-407.
27. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. Sex differences in survival for patients with glioblastoma. Neuro Oncol 2019; 21: 1181-1191.
28. Brown MA, Lien ES, Felker ER, Tanguturi SK, Chaudhuri AA, Du L, et al. Impact of MGMT methylation and sex on glioblastoma prognosis. Clin Cancer Res 2020; 26: 2227-2235.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.